Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Masucci

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Opinion on Emerging Drugs|May 31, 2023
Systemic mastocytosis: 2023 update on diagnosis and management in adultsAlessandro Costa, Emilia Scalzulli, Ida Carmosino, et al.
Frontiers in Oncology|June 23, 2023
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combinationChiara Masucci, Mauro Passucci, Emilia Scalzulli, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 12, 2024
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-upAlessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, et al.
Frontiers in Oncology|May 17, 2023
Case Report: Infectious prophylaxis in hematological malignanciesMauro Passucci, Chiara Masucci, Francesca Paoletti, et al.
Leukemia & Lymphoma|July 12, 2023
<i>CCND2</i> mutations in atypical chronic myeloid leukemia: a report of two casesGiovanni Iaquinta, Emilia Scalzulli, Silvia Angeloni, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 26, 2022
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case ReportMartina Di Palma, Elio Gentilini, Chiara Masucci, et al.
Frontiers in Oncology|July 3, 2023
Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRSChiara Masucci, Sara Pepe, Ursula La Rocca, et al.
Annals of Hematology|September 9, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapiesDanilo De Novellis, Salvatore Palmieri, Stefano Rocco, et al.
European Journal of Haematology|October 6, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsDanilo De Novellis, Daniele Derudas, Donatella Vincelli, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Emerging Drugs|May 31, 2023
Systemic mastocytosis: 2023 update on diagnosis and management in adultsAlessandro Costa, Emilia Scalzulli, Ida Carmosino, et al.
Frontiers in Oncology|June 23, 2023
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combinationChiara Masucci, Mauro Passucci, Emilia Scalzulli, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 12, 2024
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-upAlessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, et al.
Frontiers in Oncology|May 17, 2023
Case Report: Infectious prophylaxis in hematological malignanciesMauro Passucci, Chiara Masucci, Francesca Paoletti, et al.
Leukemia & Lymphoma|July 12, 2023
<i>CCND2</i> mutations in atypical chronic myeloid leukemia: a report of two casesGiovanni Iaquinta, Emilia Scalzulli, Silvia Angeloni, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 26, 2022
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case ReportMartina Di Palma, Elio Gentilini, Chiara Masucci, et al.
Frontiers in Oncology|July 3, 2023
Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRSChiara Masucci, Sara Pepe, Ursula La Rocca, et al.
Annals of Hematology|September 9, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapiesDanilo De Novellis, Salvatore Palmieri, Stefano Rocco, et al.
European Journal of Haematology|October 6, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsDanilo De Novellis, Daniele Derudas, Donatella Vincelli, et al.
Pageof 1